We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
Cases of serious liver injury with elevated transaminases and bilirubin have been reported during treatment with Kaftrio–Kalydeco combination therapy. In all patients, measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin levels before starting treatment, every 3 months during...
The CMA has found that the merger of 2 firms that make foam used in products like bedding and cleaning sponges could lead to higher prices and less choice.
Employment Tribunal decision.
It is the first treatment approved by the UK regulator that has been made possible through the Access Consortium ‘New Active Substance Work Sharing Initiative’.
The CMA has accepted a remedy from Carpenter and Recticel following concerns that Carpenter’s merger with Recticel could harm manufacturers and lead to a worse deal for shoppers on items like mattresses and kitchen sponges.
Carpenter and Recticel have asked the CMA to consider a “fast-track” remedy to address concerns that their merger could lead to manufacturers and shoppers paying more for items like mattresses and kitchen sponges.
Employment Tribunal decision
Upper Tribunal Administrative Appeals Chamber decision of Judge Perez on 28 February 2020.
Patients with pulmonary hypertension associated with idiopathic interstitial pneumonias should not be treated with riociguat in light of interim results from a recently terminated study.
Stop prescribing Picato and consider other treatment options for actinic keratosis as appropriate. The licence of ingenol mebutate (Picato) has been suspended as a precautionary measure while the European Medicines Agency (EMA) continues to investigate concerns about a possible increased...
Licensed doses and differences in potency between different inhaled corticosteroids; advice for use with spacer device.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).